Medication for Autism in Adults: What Helps (and What Doesn’t)

Most of what’s written about autism medication is aimed at parents of young children. If you’re an autistic adult, or you think you might be, those guides probably don’t answer your questions. They also rarely mention how little of the research includes adults. This article is written for you. It draws on one of the few guidelines made for autistic adults, the UK’s NICE CG142. If you’re still figuring out whether you might have autism, start with our overview of autism in adults.

Is there medication for autism?

The NICHD says no medication cures autism spectrum disorder, and NICE advises against several drug classes for core features in adults. Two medicines carry autism-related FDA approvals: risperidone (Risperdal), whose label rests on trials in children and adolescents ages 5 to 17, and Abilify (aripiprazole), whose label covers ages 6 to 17. Both cover only irritability associated with autistic disorder.

Risperdal is the brand name for risperidone, and Abilify for aripiprazole. The risperidone label defines that irritability as aggression toward others, deliberate self-injury, temper tantrums and quickly changing moods.

Off-label use means prescribing an approved drug for a disease or condition it is not approved to treat; the FDA says prescribers generally may do this when they judge it medically appropriate for their patient. Both autism-related approvals rest on trials in children and adolescents, so using either drug for irritability in an autistic adult is off-label.

Large trials aimed at autism itself have failed. Two phase III bumetanide trials, each with 211 young people, stopped early with no difference from placebo (Fuentes et al. 2023). An NIH-funded oxytocin trial in 277 young people ages 3 to 17 found no improvement in social function after 24 weeks (2021).

Medication can address the conditions that come with autism. The 2019 Lai et al. meta-analysis of 96 studies, across all ages, gave these pooled estimates:

For autistic adults alone, a 2023 review by Curnow and colleagues found that the prevalence of any psychiatric diagnosis ranged from 15.4% to 79% across 20 studies.

Which conditions each autism-related medicine is used for

An autism medication list groups medicines by the problem each treats, and only risperidone (Risperdal) and Abilify (aripiprazole) carry autism-related FDA approvals, both for irritability in children and adolescents. Every other medicine below is used for a co-occurring condition or, like melatonin, sold as a supplement.

Related reading: clonidine for anxiety and clonidine for sleep.

SSRIs block the reabsorption of serotonin, so more of it stays active between nerve cells. The SNRI venlafaxine blocks the reabsorption of serotonin and norepinephrine. Risperidone is thought to block dopamine and serotonin receptors. Aripiprazole partly activates some dopamine and serotonin receptors and blocks another serotonin receptor, according to StatPearls. Methylphenidate, a stimulant, blocks the reabsorption of dopamine and norepinephrine. Guanfacine and clonidine activate alpha-2 receptors.

How prescribing for autistic adults differs from the pediatric labels

Medication for autism in adults is off-label when used for irritability, because the autism-related labels for risperidone (Risperdal) and Abilify (aripiprazole) cover children and adolescents. The UK’s NICE guideline says to treat an autistic adult’s anxiety, depression or other coexisting condition with the medicines recommended in the guidance for that condition.

The only adult trial in a 2007 Cochrane review of risperidone was the 1998 McDougle trial in 31 adults; the reviewers said risperidone “may be beneficial” but that all the studies were relatively small. A 2023 umbrella review of 32 systematic reviews rated no intervention for autistic adults as evidence-based.

For behavior that challenges, NICE advises an antipsychotic only alongside a psychosocial intervention once other approaches have had little or no effect, prescribed by a specialist and stopped if there is no clinically important response by 6 weeks.

NICE asks prescribers to “be aware of the potential for greater sensitivity to side effects and idiosyncratic responses in autistic people and consider starting with a low dose.” The risperidone label says risperidone raises the hormone prolactin more than other antipsychotics. Prolactin-related side effects include breast enlargement or discharge and late or missed periods, as well as decreased sexual ability. Both the risperidone label and the aripiprazole label warn of weight gain and high blood sugar, along with changes in blood fats such as cholesterol and triglycerides. They recommend checking weight, and blood sugar in people with diabetes or at risk for it. Both labels also warn of tardive dyskinesia, involuntary movements that are potentially irreversible, and list akathisia (restlessness and an inability to stay still) among adverse reactions in adult trials.

When an autistic adult brings us a medication question, the first thing we pin down is the target symptom and how we’ll know it changed; then we make one change at a time. NICE advises regular review of benefit and side effects.

Medication can treat co-occurring anxiety or depression. In a 2021 study of 305 autistic adults, camouflaging (the effort of hiding autistic traits) was associated with more anxiety and depression symptoms, though an association can’t show cause. More on autism masking.

A psychiatric prescriber with autism experience (a psychiatrist or psychiatric PA) should manage this, ideally alongside CBT that NICE says should be adapted with a more concrete, structured approach and plain English. At Zellig Psychiatry, this happens in medication management.

Autism anxiety medication for adults

Autism anxiety medication for adults follows the guidance for the anxiety disorder itself, as NICE advises. For panic disorder and social anxiety disorder in the general population, NIMH describes SSRIs and SNRIs as typically the first treatment. NICE adds that a low starting dose is worth considering in autistic adults.

A 2013 Cochrane review included four adult-only trials; one small adult study showed improvement in anxiety, and the reviewers called the adult evidence limited, saying it was unclear whether the studies’ design could have skewed their results.

NIMH says buspirone must be taken daily for 3 to 4 weeks to reach full effect. Benzodiazepines are used for some short-term anxiety symptoms, and taking them over long periods may lead to tolerance or dependence. Beta-blockers manage physical symptoms such as a racing heart, sweating and tremor. See also clonidine for anxiety.

Medication for autism and ADHD when both are present

Medication for autism and ADHD starts with ADHD treatment. NICE advises that an autistic adult’s ADHD be treated with medicines informed by the ADHD guidance, with attention to possible greater sensitivity to side effects. The labels for Adderall XR, Strattera, Intuniv and Kapvay list no autism indication.

The best-known controlled trial is the 2005 RUPP Autism Network study in children with pervasive developmental disorders and hyperactivity. Methylphenidate “was often efficacious” for hyperactivity, but the response was smaller than in typically developing children with ADHD, and adverse effects were more frequent.

With your prescriber, you choose between a stimulant and a non-stimulant; AuDHD covers what having both diagnoses means.

Leucovorin autism treatment and the evidence behind it

The FDA found the evidence for leucovorin autism treatment insufficient, and Wellcovorin (leucovorin calcium) is not FDA-approved to treat autism. The FDA’s March 10, 2026 approval covers cerebral folate transport deficiency in people with a confirmed variant in the folate receptor 1 (FOLR1) gene. The AAP reports the FDA’s finding.

Cerebral folate transport deficiency is a rare genetic condition in which folate, a B vitamin, doesn’t get into the brain normally. Usually a protein called folate receptor alpha carries folate across. In this condition, that route doesn’t work well. Leucovorin (also called folinic acid) is an active form of folate that can use a second route, the reduced folate carrier, to reach the brain. That’s the reasoning behind trying it.

The autism hypothesis centers on folate receptor alpha autoantibodies (FRAAs), which interfere with that receptor and are one cause of cerebral folate deficiency. No FRAA test is FDA-cleared or approved, the AAP notes.

The idea linking leucovorin to autism centers on folate receptor alpha autoantibodies (FRAAs). These are immune proteins that block the receptor that normally carries folate into the brain, which can cause low folate in the brain. According to the American Academy of Pediatrics, no test for these antibodies is FDA-cleared or approved.

The best-known study is a 2018 trial by Frye and colleagues. It included 48 children with autism and language delays, about 7 years old on average. For 12 weeks, half took folinic acid and half took a placebo. Children on folinic acid improved more in verbal communication than children on placebo. The effect was moderate to large, and bigger in children who tested positive for the antibodies. Side effects were similar in both groups.

The authors called it a small study. It also included only children, so it doesn’t tell us whether leucovorin helps autistic adults.

A second trial in children, published in 2024 by Panda and colleagues, was retracted on January 29, 2026. A statistical review couldn’t reproduce its results (retraction notice). That leaves the Frye trial as the main controlled evidence.

In September 2025, the FDA announced leucovorin under a headline about autism symptoms. The approval itself is narrower. The Wellcovorin label covers cerebral folate transport deficiency, the genetic condition described above, which is linked to changes in the FOLR1 gene. The FDA based it on 26 published case reports covering 46 patients, not on autism trials.

Professional groups remain cautious. The American Academy of Pediatrics does not recommend routine leucovorin for autistic children. The Child Neurology Society says it “is not a standard or evidence-based therapy for individuals with autism.”

What this means for autistic adults: the studies so far were only in children, and the FDA-approved use requires a genetic diagnosis. If you’re curious about leucovorin, we can talk through whether FOLR1 genetic testing makes sense for you during a medication management visit.

Unproven options sold for autism

Transcranial magnetic stimulation (TMS) holds an electromagnet against the head, and its pulses cause small electric currents that stimulate nerve cells in a targeted brain area. The FDA has cleared repetitive TMS for treatment-resistant major depressive disorder and OCD, and autism is not among its cleared uses (Oberman et al. 2023). A 2018 meta-analysis of 23 reports found moderate effects on some measures. With most studies at moderate to high risk of bias (design flaws that could skew results), the authors judged the evidence “preliminary and insufficient, at present, to support offering TMS to treat ASD.”

Some private clinics market a branded version of TMS called MeRT (Magnetic e-Resonance Therapy) for autism. It adjusts the magnetic pulses based on each person’s EEG, a recording of brain waves. When we searched PubMed on September 16, 2026, we found no published controlled trials of MeRT for autism.

Stem cell treatment for autism involves infusing cells that some clinics claim can repair or calm the brain. A 2021 review pooled 11 small trials with 461 patients. It found some improvement on behavior rating scales and no serious side effects, but the authors said larger, better studies are needed before those results can be trusted. Stem cell treatment for autism is not FDA-approved, and the FDA warns that unapproved stem cell products can have serious safety problems.

Many other “natural” or “biomedical” autism treatments are sold online and in private clinics. For the core features of autism in adults, meaning differences in social communication and repetitive behaviors or routines, the UK’s NICE guidance advises against:

• chelation
• gluten-free, casein-free or other exclusion diets
• dietary supplements
• oxytocin
• secretin (a digestive hormone)
• hyperbaric oxygen

Two of these carry specific warnings. Chelation uses chemicals to pull heavy metals out of the body. The FDA has never approved an over-the-counter chelation product for any condition, and it warns that chelation can cause dehydration, kidney failure and death. For hyperbaric oxygen, a Cochrane review found no evidence that it improves autism symptoms.

Signs a treatment claim needs a closer look:

• It claims to cure autism or reverse it.
• It promises results within weeks.
• It’s sold only as a cash-pay package.
• It relies on testimonials instead of published studies.

Before starting anything like this, talk it over with your prescriber. If you haven’t been diagnosed yet, start with an adult autism evaluation.

How to make an autism medication decision with a prescriber

If you haven’t had an adult autism evaluation, start there. If you’re already diagnosed, go to medication management.

Questions to bring to a review visit:

Contact your prescriber promptly, or seek emergency care, if any of these appear:

If you are thinking about suicide, call or text 988.

Zellig Psychiatry offers in-person care and secure video visits statewide across Pennsylvania. Current in-person options are on our locations page, and coverage and visit costs are on our insurance and fees page.